COMP <GO>
SPRO vs ZYBT // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Spero Therapeutics Inc. (NASDAQ) VS. Zhengye Biotechnology Holding Limited (Class A) (NASDAQ) • 15-METRIC TALLY: SPRO 5
— ZYBT 4
■ METRIC PARITY
LAST: $1.04 (0.00%) • MKT CAP: $60.6M
options-implied-move
—
LAST: $1.34 (+0.75%) • MKT CAP: $63.0M
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPRO VS. ZYBT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPRO | ZYBT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 20.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.60% | -22.30% | +48.90 | SPRO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.1x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -19.53% | 2.61% | -22.14 | ZYBT | /fcf-yield <GO> |
| Operating Margin | 50.20% | -60.00% | +110.20 | SPRO | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -60.00% | +128.00 | SPRO | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | -34.80% | +214.80 | SPRO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 1.90 | -1.70 | ZYBT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | SPRO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.6 | 45.1 | -5.50 | ZYBT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $60.6M | $63.0M | -$2.5M | ZYBT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPRO REV | ZYBT REV | SPRO GROSS % | ZYBT GROSS % | SPRO FCF | ZYBT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.6M | $16.6M | — | 20.5% | -$12.6M | $1.8M |
| FY 2024 | $371.0K | $25.5M | — | 49.0% | -$23.4M | $3.8M |
| FY 2023 | $933.0K | — | — | — | -$33.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPRO // BETA —
ZYBT // BETA —